Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year. Either neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) has been shown as efficatious therapy to improve patients outcomes in esophageal or esophagogastric junction cancer as compared with surgery alone. The purpose of this study was to explore the optimal neoadjuvant treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with esophageal or esophagogastric junction cancer.
≥18 years；
Esophageal or Esophagogastric cancer；
Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa (AJCC 8th)；
Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences；
With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc；
Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer；
Existing active infection such as active tuberculosis and hepatitis；
History of myocardial infarction within the past 6 months or history of ventricular arrhythmia；